Luca Camparini graduated in Pharmaceutical Biotechnology Master Degree at University of Bologna in 2015. Then, he was awarded with a PhD position in Molecular Cardiology group at the International Centre for Genetic Engineering and Biotechnology (ICGEB, Trieste). During his PhD's studies, following the lead of Francesco Loffredo, he investigated Gdf11 effects on cardiac tissue and its future potential therapeutic use against hypertrophyc cardiomyopaties.
Crispr/Cas9 to elucidate cardiac specific effects of Gdf11
Event: ESC Congress 2019
Topic: Signal Transduction, Mechanotransduction
Session: Heart failure: pathophysiology
ESC 365 is supported by
